FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286493914> ?p ?o ?g. }

• W4286493914 endingPage "4188" @default.
• W4286493914 startingPage "4178" @default.
• W4286493914 abstract "PURPOSE Combination treatment with BRAF and MEK inhibitors has demonstrated benefits on progression-free survival (PFS) and overall survival (OS) and is a standard of care for the treatment of advanced BRAF V600–mutant melanoma. Here, we report the 5-year update from the COLUMBUS trial (ClinicalTrials.gov identifier: NCT01909453 ). METHODS Patients with locally advanced unresectable or metastatic BRAF V600–mutant melanoma, untreated or progressed after first-line immunotherapy, were randomly assigned 1:1:1 to encorafenib 450 mg once daily plus binimetinib 45 mg twice daily, vemurafenib 960 mg twice daily, or encorafenib 300 mg once daily. An updated analysis was conducted 65 months after the last patient was randomly assigned. RESULTS Five hundred seventy-seven patients were randomly assigned: 192 to encorafenib plus binimetinib, 191 to vemurafenib, and 194 to encorafenib. The 5-year PFS and OS rates with encorafenib plus binimetinib were 23% and 35% overall and 31% and 45% in those with normal lactate dehydrogenase levels, respectively. In comparison, the 5-year PFS and OS rates with vemurafenib were 10% and 21% overall and 12% and 28% in those with normal lactate dehydrogenase levels, respectively. The median duration of response with encorafenib plus binimetinib was 18.6 months, with disease control achieved in 92.2% of patients. In comparison, the median duration of response with vemurafenib was 12.3 months, with disease control achieved in 81.2% of patients. Long-term follow-up showed no new safety concerns, and results were consistent with the known tolerability profile of encorafenib plus binimetinib. Interactive visualization of the data presented in this article is available at COLUMBUS dashboard. CONCLUSION In this 5-year update of part 1 of the COLUMBUS trial, encorafenib plus binimetinib treatment demonstrated continued long-term benefits and a consistent safety profile in patients with BRAF V600–mutant melanoma." @default.
• W4286493914 created "2022-07-22" @default.
• W4286493914 creator A5001548963 @default.
• W4286493914 creator A5001893646 @default.
• W4286493914 creator A5006048202 @default.
• W4286493914 creator A5008736570 @default.
• W4286493914 creator A5009056091 @default.
• W4286493914 creator A5010492722 @default.
• W4286493914 creator A5011197831 @default.
• W4286493914 creator A5015081105 @default.
• W4286493914 creator A5016654748 @default.
• W4286493914 creator A5023174631 @default.
• W4286493914 creator A5024976681 @default.
• W4286493914 creator A5034365278 @default.
• W4286493914 creator A5050332735 @default.
• W4286493914 creator A5052136953 @default.
• W4286493914 creator A5056132643 @default.
• W4286493914 creator A5077331259 @default.
• W4286493914 creator A5089297467 @default.
• W4286493914 creator A5090633646 @default.
• W4286493914 date "2022-12-20" @default.
• W4286493914 modified "2023-10-15" @default.
• W4286493914 title "COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With <i>BRAF</i> V600–Mutant Melanoma" @default.
• W4286493914 cites W1965370740 @default.
• W4286493914 cites W2065909963 @default.
• W4286493914 cites W2116997650 @default.
• W4286493914 cites W2154841567 @default.
• W4286493914 cites W2163188200 @default.
• W4286493914 cites W2203677081 @default.
• W4286493914 cites W2491982852 @default.
• W4286493914 cites W2551317550 @default.
• W4286493914 cites W2605630889 @default.
• W4286493914 cites W2611270905 @default.
• W4286493914 cites W2624834472 @default.
• W4286493914 cites W2753432434 @default.
• W4286493914 cites W2773258053 @default.
• W4286493914 cites W2793817570 @default.
• W4286493914 cites W2885140428 @default.
• W4286493914 cites W2891205725 @default.
• W4286493914 cites W2948155539 @default.
• W4286493914 cites W2969704902 @default.
• W4286493914 cites W2982615568 @default.
• W4286493914 cites W2984713389 @default.
• W4286493914 cites W2990911279 @default.
• W4286493914 cites W2997513295 @default.
• W4286493914 cites W3013646646 @default.
• W4286493914 cites W3033241570 @default.
• W4286493914 cites W3036172056 @default.
• W4286493914 cites W3042405305 @default.
• W4286493914 cites W3043703771 @default.
• W4286493914 cites W3046543693 @default.
• W4286493914 cites W3047382685 @default.
• W4286493914 cites W3163045651 @default.
• W4286493914 cites W3165194084 @default.
• W4286493914 cites W3169238591 @default.
• W4286493914 cites W3173401695 @default.
• W4286493914 cites W3178058903 @default.
• W4286493914 cites W4256631179 @default.
• W4286493914 doi "https://doi.org/10.1200/jco.21.02659" @default.
• W4286493914 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35862871" @default.
• W4286493914 hasPublicationYear "2022" @default.
• W4286493914 type Work @default.
• W4286493914 citedByCount "42" @default.
• W4286493914 countsByYear W42864939142022 @default.
• W4286493914 countsByYear W42864939142023 @default.
• W4286493914 crossrefType "journal-article" @default.
• W4286493914 hasAuthorship W4286493914A5001548963 @default.
• W4286493914 hasAuthorship W4286493914A5001893646 @default.
• W4286493914 hasAuthorship W4286493914A5006048202 @default.
• W4286493914 hasAuthorship W4286493914A5008736570 @default.
• W4286493914 hasAuthorship W4286493914A5009056091 @default.
• W4286493914 hasAuthorship W4286493914A5010492722 @default.
• W4286493914 hasAuthorship W4286493914A5011197831 @default.
• W4286493914 hasAuthorship W4286493914A5015081105 @default.
• W4286493914 hasAuthorship W4286493914A5016654748 @default.
• W4286493914 hasAuthorship W4286493914A5023174631 @default.
• W4286493914 hasAuthorship W4286493914A5024976681 @default.
• W4286493914 hasAuthorship W4286493914A5034365278 @default.
• W4286493914 hasAuthorship W4286493914A5050332735 @default.
• W4286493914 hasAuthorship W4286493914A5052136953 @default.
• W4286493914 hasAuthorship W4286493914A5056132643 @default.
• W4286493914 hasAuthorship W4286493914A5077331259 @default.
• W4286493914 hasAuthorship W4286493914A5089297467 @default.
• W4286493914 hasAuthorship W4286493914A5090633646 @default.
• W4286493914 hasBestOaLocation W42864939142 @default.
• W4286493914 hasConcept C126322002 @default.
• W4286493914 hasConcept C197934379 @default.
• W4286493914 hasConcept C2776131300 @default.
• W4286493914 hasConcept C2777658100 @default.
• W4286493914 hasConcept C2778375690 @default.
• W4286493914 hasConcept C2994587330 @default.
• W4286493914 hasConcept C502942594 @default.
• W4286493914 hasConcept C71924100 @default.
• W4286493914 hasConceptScore W4286493914C126322002 @default.
• W4286493914 hasConceptScore W4286493914C197934379 @default.
• W4286493914 hasConceptScore W4286493914C2776131300 @default.
• W4286493914 hasConceptScore W4286493914C2777658100 @default.
• W4286493914 hasConceptScore W4286493914C2778375690 @default.

• next